Breaking News

Oscar Pistorius Sentenced to 5 Years in Prison
Tweet TWEET

Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE

Amarin Announces Notification of Patent Allowance for U.S. Application
13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication

Broadens Vascepa Claims With a Wider Range of EPA Concentrations

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of Notice of Allowance for U.S. Patent
Application Serial Number 13/614,146. This application includes claims
intended to protect the Vascepa^® (icosapent ethyl) indication approved by the
U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical
trial results.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.

The claims in this allowed application cover a method of use relating to
Vascepa's MARINE indication. Specifically, the allowed independent claim
covers use of icosapent ethyl, or EPA, including Vascepa, in lowering
triglycerides through the daily administration of about 2500 mg to about 5000
mg of EPA, independent of DHA content, present in one or more capsules,
effective to lower triglycerides in the subject by at least 25% without
increasing LDL-C by more than 5%.

"The claims in this allowed application cover the specified method of
administration of a pharmaceutical composition comprising EPA over a broad
range of daily EPA doses and amounts of EPA per capsule—including, for
example, a daily dosing regimen of 4 capsules with about 625 mg to about 1.25
grams of EPA per capsule," stated Joseph Zakrzewski, Chairman and Chief
Executive Officer of Amarin. "The issuance of this Notice of Allowance
represents yet another significant step toward Amarin's goal of protecting the
commercial potential of Vascepa to beyond 2030 through patent protection,
regulatory exclusivity, trade secrets and by taking advantage of manufacturing
barriers to entry."

This application is part of an expanding patent portfolio for Amarin with 17
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book, Amarin's
plan to protect the commercial potential of Vascepa, and the future status of
pending patent applications. These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties. Among the
factors that could cause actual results to differ materially from those
described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials and related regulatory approvals. A
further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

CONTACT: Amarin contact information:
        
         Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.